Johnson & Johnson and Coca-Cola both posted first-quarter 2026 beats, drawing capital rotating out of tech, but JNJ's 23 times forward price-to-earnings multiple for double-digit oncology growth undercuts KO's 26 times multiple, making JNJ the stronger risk-reward defensive anchor right now. JNJ revenue rose 9.9 percent to 24.062 billion dollars, with adjusted earnings per share of 2.70 dollars, driven by DARZALEX at 3.964 billion dollars, up 22.5 percent, and TREMFYA jumping 68.3 percent to 1.608 billion dollars, offsetting STELARA's 59.7 percent decline under biosimilar pressure; management raised full-year revenue guidance to a range of 100.3 billion to 101.3 billion dollars. Coca-Cola's revenue climbed 12.1 percent to 12.472 billion dollars, with earnings per share of 0.86 dollars beating estimates by 5.87 percent, but only 3 percent volume growth means most gains came from pricing that could reverse. Polymarket traders price a 92 percent chance JNJ beats its next earnings, fueled by DARZALEX and TREMFYA absorbing STELARA's erosion, while KO faces tests on volume durability outside pricing and an Africa bottling divestiture in the second half of 2026.
The Coca-Cola CompanyKO's volume growth is only 3%, with gains from pricing that could reverse, and faces tests on volume durability.
Coca-Cola Europacific Partners PLC
Johnson & JohnsonJNJ beat Q1 estimates, raised guidance, and trades at a lower P/E with strong oncology growth, making it a better defensive buy.